Delusion in the critical patient;Delirio en el paciente crítico

Medicina Intensiva

Volumn 32, Issue SUPPL. 1, 2008, Pages 77-91

  Palencia Herrejon E ^a   Romera, M A ^b   Silva, J A ^c  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c H Alarcos   (Spain)

Author keywords

Critically ill patients; Delirium; Halloperidol; Neuroleptic agents

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BROMOCRIPTINE; CLONIDINE; DANTROLENE; DEXMEDETOMIDINE; HALOPERIDOL; LORAZEPAM; METHYLPHENIDATE; MIANSERIN; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROPOFOL; RISPERIDONE; RUBIFEN; TIAPRIDE; TIAPRIZAL; TRAZODONE; ZIPRASIDONE;

AGITATION; ARTIFICIAL VENTILATION; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DELUSION; DRUG ABSORPTION; DRUG METABOLISM; EXERCISE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; VALIDATION PROCESS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CRITICAL ILLNESS; DELUSIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HALOPERIDOL; HUMANS; PROPOFOL; QUESTIONNAIRES; RISK FACTORS; RISPERIDONE; SEVERITY OF ILLNESS INDEX;

EID: 45749091455     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text revision. Washington DC, American Psychiatric Association 2000.
2. Ely EW, Siegel MD, Inouye SK. Delirium in the Intensive Care Unit: an under-recognized syndrome of organ dysfunction. Seminars Respir Crit Care Med. 2001;22:115-6.
3. Ely EW, Stephens RK, Jackson JC, Thomason JW, Truman B, Gordon S, et al. Current opinions regarding the importance, diagnosis, and management of delirium in the intensive care unit: a survey of 912 healthcare professionals. Crit Care Med. 2004;32:106-12.
4. Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, et al. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001;27:1892-1900.
5. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the Intensive Care Unit. JAMA. 2004;291:1753-62.
6. Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. The impact of different diagnostic criteria on prevalence rates for delirium. Dementia Geriatr Cognit Dis. 2003;16:156-61.
7. González M, De Pablo J, Fuente E, Valdés M, Peri JM, Nomdedeu M, et al. Instrument for detection of delirium in general hospitals: adaptation of confusion assessment method. Psychosomatics. 2004;45:426-31.
8. Guillén Lera F. Delirium en pacientes ancianos hospitalizados. Med Clin (Barc.). 2005;124:538-40.
9. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001;286:2703-10.
10. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001;29:1370-9.
11. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Scrrening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27:859-64.
12. Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289:2983-91.
13. Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. Confusion assessment method in the diagnostics of delirium among aged hospital patients: would it serve better in screening than as a diagnostic instrument? Int J Geriatr Psychiatry. 2002;17:1112-9.
14. Bergeron N, Skrobik Y, Dubois MJ. Is disturbance of consciousness an important feature of ICU delirium? Intensive Care Med. 2005;31:887.
15. Lin SM, Liu CY, Wang CH, Lin HC, Huang CD, Huang PY, et al. The impact of delirium on the survival of mechanically ventilated patients. Crit Care Med. 2004;32:2254-9.
16. Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340:669-76.
17. Meagher DJ, O'Hanlon D, O'Mahony E, Casey PR, Trzepacz PT. Relationship between symptoms and motoric subtype of delirium. J Neuropsychiatry Clin Neurosci. 2000;12:51-6.
18. O'Keefe ST, Lavan JN. Clinical significance of delirium subtypes in older people. Age Ageing. 1999;28:115-9.
19. Levkoff SE, Evans DA, Liptzin B, Cleary PD, Lipsitz LA, Wetle TT, et al. Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med. 1992;152:334-40.
20. McNicoll L, Pisani MA, Zhang Y, Ely EW, Siegel MD, Inouye SK. Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc. 2003;51:591-8.
21. Kiely DK, Bergmann MA, Murphy KM, Jones RN, Orav EJ, Marcantonio ER. Delirium among newly admitted postacute facility patients: prevalence, symptoms, and severity. J Gerontol A Biol Sci Med Sci. 2003;58:M441-5.
22. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale . J Pain Symptom Manage. 1997;13:128-37.
23. McCusker J, Cole M, Bellavance F, Primeau F. Reliability and validity of a new measure of severity of delirium. Int Psychogeriatr. 1998;10:421-33.
24. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med. 2004;30:444-9.
25. Milbrandt EB, Deppen S, Harrison PL, Shintani AK, Speroff T, Stiles RA, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32:955-62.
26. Kalisvaart KJ, de Jonghe JF, Bogaards MJ, Vreeswijk R, Egberts TC, Burger BJ, et al. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc. 2005;53:1658-66.
27. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry. 1999;156 Suppl 5:1-20.
28. Meagher DJ. Delirium: optimising management. BMJ. 2001;322:144-9.
29. Inouye SK. Delirium in older persons. N Engl J Med. 2006;354:1157-65.
30. Romera MA, Chamorro C, Nieto M, Estecha MA, Molina JM, Rubio JJ. Valoración y tratamiento de la agitación en pacientes críticos. An C Intensivos. 1992;7:55-68.
31. Cavaliere F, D'Ambrosio F, Volpe C, Masieri S. Postoperative delirium. Curr Drug Targets. 2005;6:807-14.
32. Fong HK, Sands LP, Leung JM. The role of postoperative analgesia in delirium and cognitive decline in elderly patients: a systematic review. Anesth Analg. 2006;102:1255-66.
33. Lundstrom M, Edlund A, Karlsson S, Brannstrom B, Bucht G, Gustafson Y. A multifactorial intervention program reduces the duration of delirium, length of hospitalization, and mortality in delirious patients. J Am Geriatr Soc. 2005;53:622-8.
34. Milliken D. Death by restraint. CMAJ. 1998;158:1611-2.
35. Bray K, Hill K, Robson W, Leaver G, Walker N, O'Leary M, et al. British Association of Critical Care Nurses position statement on the use of restraint in adult critical care units. Nurs Crit Care. 2004;9:199-212.
36. Maccioli GA, Dorman T, Brown BR, Mazuski JE, McLean BA, Kuszaj JM, et al. Clinical practice guidelines for the maintenance of patient physical safety in the intensive care unit: Use of restraining therapies - American College of Critical Care Medicine Task Force 2001-2002. Crit Care Med. 2003;31:2665-76.
37. Someya T, Endo T, Hara T, Yagi G, Suzuki J. A survey on the drug therapy for delirium. Psychiatry Clin Neurosci. 2001;55:397-401.
38. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119-41.
39. Carnes M, Howell T, Rosenberg M, Francis J, Hildebrand C, Knuppel J. Physicians vary in approaches to the clinical management of delirium. J Am Geriatr Soc. 2003;51:234-9.
40. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics. 2002;43:183-94.
41. Stagno D, Gibson C, Breitbart W. The delirium subtypes: a review of prevalence, phenomenology, pathophysiology, and treatment response. Palliat Support Care. 2004;2:171-9.
42. Michaud L, Bula C, Berney A, Camus V, Voellinger R, Stiefel F, et al, Delirium Guidelines Development Group. Delirium: guidelines for general hospitals. J Psychosom Res. 2007;62:371-83.
43. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother. 2006;40:1966-73.
44. Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry. 2007;68:11-21.
45. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;Issue 2. CD005594.
46. Fish DN. Treatment of delirium in the critically ill patient. Clin Pharm. 1991;10:456-66.
47. Hassan E, Fontaine DK, Nearman HS. Therapeutic considerations in the management of agitated or delirious critically ill patients. Pharmacotherapy. 1998;18:113-29.
48. Tesar GE, Stern TA. Rapid tranquilization of the agitated intensive care unit patient. J Intensive Care Med. 1988;3:195-201.
49. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37:435-56.
50. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72:438-52.
51. Avent KM, Riker RR, Fraser GL, Van der Schyf CJ, Usuki E, Pond SM. Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci. 1997;61:2383-90.
52. Heckers S, Tesar GE, Querques JM, Stern TA. Diagnosis and treatment of agitation and delirium in the intensive care unit. En: Irwin RS, Rippe JM, editors. Intensive Care Medicine. 5th ed. New York: Lippincott Williams & Wilkins. 2003. p. 2153-62.
53. Brown TM, Boyle MF. Delirium. BMJ. 2002;325:644-7.
54. Pandharipande P, Jackson J, Ely EW. Delirium: acute cognitive dysfunction in the critically ill. Curr Opin Crit Care. 2005;11:360-8.
55. Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, et al. The relationship between D2 receptor occupancy and plasma levels on low dose haloperidol: a PET study. Psychopharmacology. 1997;131:148-52.
56. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153:948-50.
57. Sanders KM, Murray GB, Cassem NH. High-dose intravenous haloperidol for agitated delirium in a cardiac patient on intraaortic balloon pump. J Clin Psychopharmacol. 1991;11:146-7.
58. Levenson JL. High-dose intravenous haloperidol for agitated delirium following lung transplantation. Psychosomatics. 1995;36:66-8.
59. Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 1994;22:433-43.
60. Fernandez F, Holmes VF, Adams F, Kavanaugh JJ. Treatment of severe refractory agitation with a haloperidol drip. J Clin Psychiatry. 1988;49:239-41.
61. Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother. 1995;29:690-3.
62. Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy. 1997;17:531-7.
63. Tauscher J, Tauscher-Wisniewski S, Kasper S. Treatment of patients with delirium. Am J Psychiatry. 2000;157:1711.
64. Platt MM, Breitbart W, Smith M, Marotta R, Weisman H, Jacobsen PB. Efficacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci. 1994;6:66-7.
65. Karnik NS, Joshi SV, Paterno C, Shaw R. Subtypes of pediatric delirium: a treatment algorithm. Psychosomatics. 2007;48:253-7.
66. Riker RR, Fraser GL, Richen P. Movement disorders associated with withdrawal from high-dose intravenous haloperidol therapy in delirious ICU patients. Chest. 1997;111:1778-81.
67. Cassem EH, Lake CR, Boyer WF. Psychopharmacology in the ICU. En: Chernow B, editor. The Pharmacology Approach to the Critically Ill patient. 3th ed. Baltimore: Williams & Wilkins; 1994. p. 651-65.
68. Menza MA, Murray GB, Holmes VF, Rafuls WA. Decreased extrapiramidal reactions with the use of intravenous haloperidol. J Clin Psychiatry. 1987;48:278-80.
69. Menza MA, Murray GB, Holmes VF, Rafuls WA. Controlled study of extrapiramidal reactions in the management of delirious medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. Heart Lung. 1988;17:238-41.
70. Sanders KM, Minnema AM, Murray GB. Low incidence of extrapyramidal symptoms in treatment of delirium with intravenous haloperidol and lorazepam in the intensive care unit. J Intensive Care Med. 1989;4:201-4.
71. Ananth J, Aduri K, Parameswaran S, Gunatilake S. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatrica. 2004:16:219-28.
72. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;146:870-6.
73. Reulbach U, Dutsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11:R4.
74. Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol. 1998;81:238-40.
75. Milbrandt EB, Kersten A, Kong L, Weissfeld LA, Clermont G, Fink MP, et al. Haloperidol use is associated with lower hospital mortality in mechanically ventilated patients. Crit Care Med. 2005;33:226-9.
76. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 2005;10:79-104.
77. Schwartz TL, Masand PS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics. 2002;43:171-4.
78. Boettger S, Breitbart W. Atypical antipsychotics in the management of delirium: a review of the empirical literature. Palliat Support Care. 2005;3:227-37.
79. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I. Pharmacology, pharmacokinetics and efficacy. Ann Pharmacother. 1999;33:73-85.
80. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics. 1998;39:422-30.
81. Kim KS, Pae CU, Chae JH, Bahk WM, Jun T. An open pilot trial of olanzapine for delirium in the Korean population. Psychiatry Clin Neurosci. 2001;55:515-9.
82. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002;43:175-82.
83. Jibson MD. Overview of antipsychotic medications. Up To Date. 2007.
84. Markowitz JS, DeVane CL, Malcolm RJ, Gefroh HA, Wang JS, Zhu HJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol. 2006;46:164-71.
85. Horikawa N, Yamazaki T, Miyamoto K, Kurosawa A, Oiso H, Matsumoto F, et al. Treatment for delirium with risperidone: results of a prospective open trial with 10 patients. Gen Hosp Psychiatry. 2003;25:289-92.
86. Parellada E, Baeza I, de Pablo J, Martínez G. Risperidone in the treatment of patients with delirium. J Clin Psychiatry. 2004;65:348-53.
87. Mittal D, Jimerson NA, Neely EP, Johnson WD, Kennedy RE, Torres RA, et al. Risperidone in the treatment of delirium: results from a prospective open-label trial. J Clin Psychiatry. 2004;65:662-7.
88. Liu CY, Juang YY, Liang HY, Lin NC, Yeh EK. Efficacy of risperidone in treating the hyperactive symptoms of delirium. Int Clin Psychopharmacol. 2004;19:165-8.
89. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004;45:297-301.
90. Schieveld JN, Leroy PL, van Os J, Nicolai J, Vos GD, Leentjens AF. Pediatric delirium in critical illness: phenomenology, clinical correlates and treatment response in 40 cases in the pediatric intensive care unit. Intensive Care Med. 2007;33:1033-40.
91. Young CC, Lujan E. Intravenous ziprasidone for treatment of delirium in the intensive care unit. Anesthesiology. 2004;101:794-5.
92. Ravona-Springer R, Dolberg OT, Hirschmann S, Grunhaus L. Delirium in elderly patients treated with risperidone: a report of three cases. J Clin Psychopharmacol. 1998;18:171-2.
93. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf. 2003;2:21-35.
94. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome-a case review. Hum Psychopharmacol Clin Exp. 2003;18:301-9.
95. Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20:243-51.
96. Czekalla J, Kollack-Walker S, Beasley C. Cardiac safety of olanzapine: comparison with other atypical and atypical antipsychotics. J Clin Psychiatry. 2001;62 Suppl 2:35-40.
97. Harrigan EP, Miceli JJ, Anziano RA, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62-9.
98. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-43.
99. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445-8.
100. Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry. 2007;15:416-24.
101. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med. 2005;353:2335-41.
102. Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology. 2004:175:1-6.
103. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-74.
104. Varma MK, Connolly K, Fulton B. Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature. J Intensive Care Med. 2007;22:52-5.
105. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, et al. The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001;16 Suppl 1:S29-34.
106. Allain H, Dautzenberg PHJ, Maurer K, Schuck S, Bonhomme D, Gérard D. Double-blind study of tiapride versus haloperidol and placebo in agitation and aggresiveness in elderly patients with cognitive impairment. Psychopharmacology. 2000;148:361-6.
107. Peters DH, Faulds D. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs. 1994;47:1010-32.
108. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153:231-7.
109. Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR, Dittus RS, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104:21-6.
110. Mayo-Smith MF, Beecher LH, Fischer TL, Gorelick DA, Guillaume JL, Hill A, et al. Working Group on the Management of Alcohol Withdrawal Delirium, Practice Guidelines Committee, American Society of Addiction Medicine. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004;164:1405-12.
111. Ntais C, Pakos E, Kyzas P, Ioannidis JPA. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2005, Issue 3: CD005063.
112. Crippen DW. Pharmacologic treatment of brain failure and delirium. Crit Care Clin. 1994;10:733-66.
113. McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med. 2000;28:1781-4.
114. Maldonado JR, Wysong A, van der Starre PJ, Block T, Reitz B. Postoperative sedation can dramatically alter the development of delirium after cardiac surgery. Psychosomatics. 2005;46:185.
115. Okamoto Y, Matsuoka Y, Sasaki T, Jitsuiki H, Horiguchi J, Yamawaki S. Trazodone in the treatment of delirium. J Clin Psychopharmacol. 1999;19:280-2.
116. Nakamura J, Uchimura N, Yamada S, Nakazawa Y. Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. Int Clin Psychopharmacol. 1997;12:147-52.
117. Morita T, Otani H, Tsunoda J, Inoue S, Chihara S. Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer. 2000;8:134-7.
118. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005;30:100-7.
119. Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium in dementia: implications for future research. J Geriatr Psychiatry Neurol. 1998;11:159-61.
120. Liptzin B, Laki A, Garb JL, Fingeroth R, Krushell R. Donepezil in the prevention and treatment of post-surgical delirium. Am J Geriatr Psychiatry. 2005;13:1100-6.